Search results
Showing 401 to 450 of 1282 results for long term conditions
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.
Show all sections
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.
This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.
Kidney conditions: CKD and blood pressure when ACR less than 70 (IND235)
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of less than 70 mg/mmol, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM217
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.
This quality standard covers decision making in people aged 16 and over, using health and social care services who may lack capacity to make their own decisions (now or in the future). It aims to support implementation of the aims and principles of the Mental Capacity Act 2005 and relevant Codes of Practice. It is not a substitute for these.
Interventional procedures programme manual
This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS45Show all sections
Sections for QS45
- Quality statements
- Quality statement 1: Initial assessment – physical examination
- Quality statement 2: Initial assessment – urinary frequency and volume chart
- Quality statement 3: Initial assessment – advice on lifestyle interventions
- Quality statement 4: Conservative management – temporary containment products
- Quality statement 5: Conservative management – urethral milking
- Quality statement 6: Medication review
- Quality statement 7: Specialist assessment – flow rate and post-void residual volume
Managing medicines for adults receiving social care in the community (NG67)
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This novel approach involves people attending a group session on medicines, and then having the option of reviewing their medicines individually in a 3/4-hour session with two health professionals
Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.
NICE's impact on managing infections in children
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.
View recommendations for TA489Show all sections
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.
Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.
View recommendations for IPG769Show all sections
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Evidence-based recommendations on collagen injection for vocal cord augmentation. This involves injecting collagen into the affected vocal cord(s).
View recommendations for IPG130Show all sections
Sections for IPG130
This indicator covers the percentage of patients on the CKD register and currently treated with an ARB or an ACE inhibitor who are also currently treated with an SGLT2 inhibitor if they have either: no type 2 diabetes and a urine ACR of 22.6 mg/mmol or more, or type 2 diabetes and a urine ACR 3 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM246
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on ab interno canaloplasty for open-angle glaucoma. This involves widening the channel that drains fluid from the eye. The aim is to reduce pressure in the eye.
View recommendations for IPG745Show all sections
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis (IPG746)
Evidence-based recommendations on tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis. This involves inserting a catheter under the skin in the abdomen to drain excess fluid when needed, at home or in community care. The aim is to reduce the need for hospital admissions and improve quality of life.
View recommendations for IPG746Show all sections
prolonged sitting and inactivity and maximise their strength at a stage of the condition when exercise was often difficult or...
Transvaginal laser therapy for stress urinary incontinence (IPG696)
Evidence-based recommendations on transvaginal laser therapy for urinary stress incontinence. This involves using a laser in the vagina to strengthen the vaginal walls, to help support the bladder and reduce symptoms of urinary stress incontinence.
View recommendations for IPG696Show all sections
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.
This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.
Familial hypercholesterolaemia: identification and management (CG71)
This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Evidence-based recommendations on high-intensity focused ultrasound for glaucoma in adults. This involves using high-intensity ultrasound to destroy a small amount of the tissue that makes fluid in the eye.
View recommendations for IPG661Show all sections
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247
Social, emotional and mental wellbeing in primary and secondary education (NG223)
This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.
Introduction of a structured approach to cognitive rehabilitation for critical care patients
cognitive rehabilitation to critical care patients at high risk of developing long-term non-physical symptoms e.g....
Evidence-based recommendations on cryotherapy for chronic rhinitis. This involves destroying a nerve in the nose to reduce chronic rhinitis symptoms.
View recommendations for IPG771Show all sections
Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.
A dietetic-led coeliac service incorporating group education
contact for colleagues requiring further advice or information on the condition. Reasons for implementing your project Gloucestershire
This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.
This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS209Show all sections
Sections for QS209
- Quality statements
- Quality statement 1: Preventing type 2 diabetes
- Quality statement 2: Structured education programme
- Quality statement 3: Continuous glucose monitoring for adults on multiple daily insulin injections who cannot self-monitor using capillary blood glucose monitoring
- Quality statement 4: Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose
- Quality statement 5: Treatment with an SGLT2 inhibitor
- Quality statement 6: 9 key care processes
- Quality statement 7: Assessing the risk of diabetic foot problems on admission to hospital
Endo-SPONGE for treating low rectal anastomotic leak (MTG63)
Evidence-based recommendations on Endo-SPONGE for treating low rectal anastomotic leak.
View recommendations for MTG63Show all sections